NCT06857747View on ClinicalTrials.gov

Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.

NANot yet recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

April 1, 2026

Conditions

Breast Cancer

Interventions

DRUG

Capecitabine

metronomic capecitabine, 500 mg, tid， po

DRUG

Vinorelbine

metronomic vinorelbine, 40mg/d, TIW1, po

DRUG

Etoposide

metronomic etoposide, 50mg/d, po

All Listed Sponsors

lead

QIAO LI

OTHER